A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

被引：0
|
作者：
Kenjiro Aogi
Hiroshi Sakai
Hirohisa Yoshizawa
Norikazu Masuda
Nobuyuki Katakami
Yasuhiro Yanagita
Kenichi Inoue
Masaru Kuranami
Mitsuhiro Mizutani
Noriyuki Masuda
机构：
[1] National Hospital Organization Shikoku Cancer Center,Department of Breast Oncology
[2] Saitama Cancer Center,Department of Thoracic Oncology
[3] Niigata University Medical and Dental Hospital,Bioscience Medical Research Center
[4] National Hospital Organization Osaka National Hospital,Department of Surgery
[5] Institute of Biomedical Research and Innovation,Division of Integrated Oncology
[6] Gunma Cancer Center,Department of Breast Oncology
[7] Saitama Cancer Center,Department of Breast Oncology
[8] Kitasato University School of Medicine,Department of Surgery
[9] Aichi Cancer Center Aichi Hospital,Department of Breast Surgery
[10] Kitasato University School of Medicine,Department of Respiratory Medicine
来源：
Supportive Care in Cancer | 2012年 / 20卷
关键词：
Palonosetron; 5-HT; receptor antagonist; Antiemetic; Chemotherapy-induced nausea and vomiting; Highly emetogenic chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1507 / 1514
页数：7
相关论文
共 50 条
  • [1] A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy
    Aogi, Kenjiro
    Sakai, Hiroshi
    Yoshizawa, Hirohisa
    Masuda, Norikazu
    Katakami, Nobuyuki
    Yanagita, Yasuhiro
    Inoue, Kenichi
    Kuranami, Masaru
    Mizutani, Mitsuhiro
    Masuda, Noriyuki
    SUPPORTIVE CARE IN CANCER, 2012, 20 (07) : 1507 - 1514
  • [2] A JAPANESE PHASE III OPEN-LABEL STUDY TO ASSESS SAFETY AND EFFICACY OF PALONOSETRON (PALO) 0.75 MG IV FOR PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN REPEATED CYCLES OF HIGHLY EMETOGENIC CHEMOTHERAPY. PALO JAPANESE COOPERATIVE STUDY GROUP
    Sakai, H.
    Aogi, K.
    Yoshizawa, H.
    Masuda, N.
    Katakami, N.
    Yanagita, Y.
    Inoue, K.
    Kuranami, M.
    Mizutani, M.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 274 - 274
  • [3] SAFETY AND EFFICACY OF ORAL PALONOSETRON IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) OVER MULTIPLE CYCLES OF MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)
    Voisin, D.
    Grunberg, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 507 - 507
  • [4] Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
    Sachin, Hingmire
    Nirmal, Raut
    SOUTH ASIAN JOURNAL OF CANCER, 2015, 4 (01) : 7 - 10
  • [5] Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV): Efficacy and safety over multiple cycles of highly or moderately emetogenic chemotherapy
    Rapoport, B.
    Schwartzberg, L.
    Chasen, M.
    Poma, A.
    Arora, S.
    Navari, R.
    Schnadig, I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S212 - S213
  • [6] Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy
    Choi, Brian S.
    Borsaru, Gabriela P.
    Ballinari, Gianluca
    Voisin, Daniel
    Di Renzo, Nicola
    LEUKEMIA & LYMPHOMA, 2014, 55 (03) : 544 - 550
  • [7] Phase III study of palonosetron for preventing chemotherapy-induced nausea and vomiting in pediatric patients
    Koga, Yuhki
    Kosaka, Yoshiyuki
    Koh, Katsuyoshi
    Matsumoto, Kimikazu
    Kumamoto, Tadashi
    Fujisaki, Hiroyuki
    Ishida, Yuji
    Suzuki, Ryoko
    Mochizuki, Shinji
    Goto, Hiroaki
    Yuza, Yuki
    Hara, Junichi
    ANNALS OF ONCOLOGY, 2021, 32 : S284 - S284
  • [8] Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study
    Tan, M
    Xu, R
    Seth, R
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (06) : 879 - 882
  • [9] Efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
    Aapro, M.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Lorusso, V.
    Karthaus, M.
    Grunberg, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S266 - S266
  • [10] Palonosetron versus ondansetron in CINV (chemotherapy-induced nausea and vomiting)
    Vieira, S.
    Monroe, D.
    Sorita, R.
    Palomar, M.
    Librojo, M.
    Porin, L.
    Ng, J.
    Taylor, A.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S370 - S370
12345